Diagnostic value of sialyl-Tn immunocytochemistry in breast cancer presenting with pathological nipple discharge.
Adult
Antigens, Tumor-Associated, Carbohydrate
/ analysis
Biomarkers, Tumor
/ analysis
Biopsy
Breast
/ immunology
Breast Neoplasms
/ complications
Carcinoma, Ductal, Breast
/ complications
Carcinoma, Intraductal, Noninfiltrating
/ complications
Confidence Intervals
Female
Humans
Hyperplasia
/ immunology
Immunohistochemistry
Logistic Models
Nipple Discharge
/ immunology
Odds Ratio
Papilloma, Intraductal
/ complications
Receptor, ErbB-2
/ analysis
Risk Factors
Sensitivity and Specificity
breast cancer
cytopathology
diagnosis
pathological nipple discharge
sialyl-Tn
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
29
10
2020
revised:
06
02
2021
accepted:
07
02
2021
pubmed:
20
2
2021
medline:
17
7
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
Mucin-associated sialyl-Tn (sTn) antigen is overexpressed and related with adverse outcome in breast cancer (BC). The role of sTn in BC has not been well defined in pathological nipple discharge (PND) cytology. The authors examined sTn immunocytochemistry (ICC) in PND to determine whether it could be a biomarker of malignancy or aggressive disease. PND was subjected to immunocytochemical staining for sTn antigen expression and thinprep cytology test (TCT) for enhancing the sensitivity and specificity. The examination data was compared with histological findings of subsequent biopsy specimens. Logistic regression analysis was used to determine which factors were most associated with malignant breast lesions. PND specimens were collected including 120 cases of intraductal papilloma, 24 cases of hyperplasia, 45 cases of ductal carcinoma in situ (DCIS), and 48 cases of invasive ductal carcinoma (IDC). STn ICC differentiated BC from benign intraductal lesions with a low sensitivity of 41.9% and a high specificity of 95.8%, but increased in combination with TCT to 64.5% and 100%, respectively. A high degree of concordance was observed between the results of sTn expression in cell smears and histological specimens. Moreover, the sTn expression was strongly associated with HER2-positive IDC (p = 0.039). Multivariate logistic analysis showed that positive sTn expression (OR: 14.241, 95%CI: 2.574, 78.794, p = 0.010) and accompanying mass (OR: 3.307, 95%CI: 1.073, 10.188, p = 0.037) were statistically significant independent risk factors for malignant PND. Mucin-associated sTn expression in PND cytology appears to be a reliable diagnostic marker for BC patients with the chief complaint of malignant nipple discharge and indicates a more aggressive behavior in IDC.
Sections du résumé
BACKGROUND
Mucin-associated sialyl-Tn (sTn) antigen is overexpressed and related with adverse outcome in breast cancer (BC). The role of sTn in BC has not been well defined in pathological nipple discharge (PND) cytology. The authors examined sTn immunocytochemistry (ICC) in PND to determine whether it could be a biomarker of malignancy or aggressive disease.
METHODS
PND was subjected to immunocytochemical staining for sTn antigen expression and thinprep cytology test (TCT) for enhancing the sensitivity and specificity. The examination data was compared with histological findings of subsequent biopsy specimens. Logistic regression analysis was used to determine which factors were most associated with malignant breast lesions.
RESULTS
PND specimens were collected including 120 cases of intraductal papilloma, 24 cases of hyperplasia, 45 cases of ductal carcinoma in situ (DCIS), and 48 cases of invasive ductal carcinoma (IDC). STn ICC differentiated BC from benign intraductal lesions with a low sensitivity of 41.9% and a high specificity of 95.8%, but increased in combination with TCT to 64.5% and 100%, respectively. A high degree of concordance was observed between the results of sTn expression in cell smears and histological specimens. Moreover, the sTn expression was strongly associated with HER2-positive IDC (p = 0.039). Multivariate logistic analysis showed that positive sTn expression (OR: 14.241, 95%CI: 2.574, 78.794, p = 0.010) and accompanying mass (OR: 3.307, 95%CI: 1.073, 10.188, p = 0.037) were statistically significant independent risk factors for malignant PND.
CONCLUSIONS
Mucin-associated sTn expression in PND cytology appears to be a reliable diagnostic marker for BC patients with the chief complaint of malignant nipple discharge and indicates a more aggressive behavior in IDC.
Identifiants
pubmed: 33605547
doi: 10.1002/cam4.3793
pmc: PMC7940227
doi:
Substances chimiques
Antigens, Tumor-Associated, Carbohydrate
0
Biomarkers, Tumor
0
sialosyl-Tn antigen
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1783-1790Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cell Mol Biol (Noisy-le-grand). 2017 Feb 28;63(2):92-95
pubmed: 28364788
Cancer. 1997 Dec 15;80(12):2240-9
pubmed: 9404700
Cancer Detect Prev. 2004;28(1):27-31
pubmed: 15041074
Cancer Manag Res. 2020 Feb 11;12:1017-1027
pubmed: 32104083
Cancer Res. 1996 May 1;56(9):2229-32
pubmed: 8616877
Cancer Res. 1993 Apr 1;53(7):1706-8
pubmed: 8453646
Clin Breast Cancer. 2010 Jun;10(3):238-45
pubmed: 20497923
Breast J. 2006 Sep-Oct;12(5 Suppl 2):S210-7
pubmed: 16959004
Surgeon. 2010 Oct;8(5):252-8
pubmed: 20709281
Biomolecules. 2012 Oct 11;2(4):435-66
pubmed: 24970145
Cancer Res. 2008 Mar 15;68(6):1636-46
pubmed: 18339842
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32452513
PLoS One. 2018 Jul 27;13(7):e0201314
pubmed: 30052649
Onkologie. 2010;33(6):307-12
pubmed: 20523094
Eur J Surg Oncol. 2009 Jun;35(6):573-7
pubmed: 18986790
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11549-54
pubmed: 26617889
Int J Mol Sci. 2016 Feb 24;17(3):275
pubmed: 26927062
Oncology. 2001;61(4):299-305
pubmed: 11721177
PLoS One. 2015 May 07;10(5):e0125994
pubmed: 25951175
Pathol Res Pract. 1996 Dec;192(12):1181-6
pubmed: 9182286
BMC Cancer. 2017 May 2;17(1):300
pubmed: 28464874
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6868-71
pubmed: 16203776
J Hematol Oncol. 2019 Dec 21;12(1):140
pubmed: 31864424
Adv Exp Med Biol. 2001;491:369-402
pubmed: 14533809